At the request of the author, and with the agreement of the journal editors, the following article has been retracted and is re-published as open access in January 2022.
Song H-Y, Xia J-S, Chen Y-G, Chen L. (2021) Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells in vitro. Human and Experimental Toxicology 40(12S): S646–S653. DOI: 10.1177/09603271211052989
References
1.
HohmannNHaefeliWEMikusG. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol2016; 12(5): 479–497.
2.
BedadaSKNeeratiP. Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats. Naunyn Schmiedebergs Arch Pharmacol2018; 391(2): 115–121.
3.
KandelSEHanLWMaoQet al.Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos2017; 45(12): 1266–1275.
4.
ZhouXGaoYYHuJYet al.Effect of breviscapine on CYP3A metabolic activity in healthy volunteers. Eur J Clin Pharmacol2018; 74(1): 37–44.
5.
SchuetzEGThummelKE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol2002; 62: 162–172.
6.
WatkinsPBDalyAWrightonSAet al.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet2001; 27: 383–391.
7.
WilliamsJARingBJCantrellVEet al.Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos2002; 30: 883–891.
8.
RagiaGDahlMLManolopoulosVG. Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs. Curr Drug Metab2016; 17(3): 227–236.
9.
SalamehGAl HadidiKEl KhateebMet al.Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol2012; 34(1): 23–33.
10.
van SchaikRHvan der HeidenIPvan den AnkerJNet al.CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem2002; 48(10): 1668–1671.
11.
KuczynskiEALeeCRManSet al.Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma. Cancer Res2015; 75(12): 2510–2519.
12.
GuoXGWangZHDongWet al.Specific CYP450 genotypes in the Chinese population affect sorafenib toxicity in HBV/HCV-associated hepatocellular carcinoma patients. Biomed Environ Sci2018; 31(8): 586–595.
13.
HtunYYSweHKSawTM. CYP3A5*3 genetic polymorphism and tacrolimus concentration in myanmar renal transplant patients. Transpl Proc2018; 50(4): 1034–1040.
14.
GillaniTBRawlingTMurrayM. Cytochrome P450-mediated biotransformation of sorafenib and its N-oxide metabolite: implications for cell viability and human toxicity. Chem Res Toxicol2015; 28(1): 92–102.
15.
CabralLKDTiribelliCSukowatiCHC. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity. Cancers (Basel)2020; 12(6): 1576–1582.
16.
Dal BoMDe MattiaEBabociLet al.New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resist Updat2020; 51: 1007–1012.
17.
QianYYuLZhangXHet al.genetic polymorphism on the pharmacokinetics and pharmacodynamics of platelet-derived growth factor receptor (PDGFR) kinase inhibitors. Curr Drug Metab2018; 19(14): 1168–1181.
18.
VarshneyESahaNTandonMet al.Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory. Springerplus2012; 1: 34–42.
19.
DestaZZhaoXShinJGet al.Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet2002; 41(12): 913–958.
20.
SwenJJNijenhuisMde BoerAet al.Pharmacogenetics: from bench to byte an update of guidelines. Clin Pharmacol Ther2011; 89(5): 662–673.
21.
Favela-MendozaAFMartinez-CortesGHernandez-ZaragozaMet al.Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype. J Genet2015; 94(1): 3–7.
LiangYHanWYanHet al.Association of *3 polymorphisms and prostate cancer risk: A meta-analysis. J Cancer Res Ther2018; 14(Suppl): S463–S467.
24.
PearceRELuWWangYet al.Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos2008; 36(8): 1637–1649.
25.
XuMZhangSZhaoHet al.Association between nucleotide-binding oligomerization domain protein 2 gene polymorphisms and Parkinson's disease (PD) susceptibility. Artif Cells Nanomed Biotechnol2019; 47: 126–132.
26.
DandaraCBalloRParkerMI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett2005; 225: 245–253.
27.
MagliuloLDahlMLLombardiGet al.Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?Eur J Clin Pharmacol2011; 67: 876–889.
